| 洪怡 刘海 李玮 游忠岚 邓樱.氨曲南联合恩替卡韦对肝硬化原发性腹膜炎患者血清甲状腺激素水平及
临床疗效的影响[J].,2017,17(3):540-543 |
| 氨曲南联合恩替卡韦对肝硬化原发性腹膜炎患者血清甲状腺激素水平及
临床疗效的影响 |
| Effects of Aztreonamcombined with Entecavir on SerumLevels of ThyroidHormone in Patients with Hepatitis B Liver Cirrhosis Primary Peritonitis andIts Clinical Efficacy |
| |
| DOI： |
| 中文关键词: 氨曲南 恩替卡韦 乙肝肝硬化 原发性腹膜炎 甲状腺激素 |
| 英文关键词: Aztreonam Entecavir Hepatitis B liver cirrhosis Primary peritonitis Thyroid hormone |
| 基金项目:四川省自然科学基金青年基金项目(B20140956） |
|
| 摘要点击次数: 924 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探讨氨曲南联合恩替卡韦对乙肝肝硬化原发性腹膜炎患者血清甲状腺激素水平及临床疗效的影响。方法：选择于我
院就诊的乙肝肝硬化原发性腹膜炎患者60 例，根据电脑生成的随机数字表将所有患者随机分为实验组和对照组，每组各30 例，
对照组患者给予氨曲南进行治疗，实验组患者在对照组的基础上联合应用恩替卡韦进行治疗。比较治疗前后两组患者血清甲状
腺激素、中性粒细胞比例、血白细胞及腹水细胞水平，并对治疗前后两组患者的体重、腹围及24 h尿量进行记录。结果：与治疗前
相比，两组患者血清TSH 水平、体重、腹围均降低，FT3、FT4、T3、T4 水平及24 h 尿量升高（P＜0.05）；与对照组相比，实验组患者
血清TSH 水平、体重、腹围较低，FT3、FT4、T3、T4 水平及24h 尿量较高（P＜0.05）；临床总有效率较高（P＜0.05）。结论：氨曲南联
合恩替卡韦对乙肝肝硬化原发性腹膜炎具有较好的临床疗效，推测其机制与改善甲状腺激素水平，降低炎症反应有关。 |
| 英文摘要: |
| Objective:To investigate the effects of aztreonamcombined with entecavir on the levels of serumthyroid hormone and
its clinical efficacy for patients with hepatitis B liver cirrhosis primary peritonitis.Methods:60 patients with hepatitisB liver cirrhosis primary
peritonitis who were treated in our hospital were selected and randomly divided into experiment group and control group, with 30
cases in each group. Patients in the control group were treated with aztreonam, patients in the experiment group were treated with entecavir
on the base of the control group. The serum thyroid hormone, neutrophils ratio, blood white cells and ascites cell levels of the two
groups were compared before and after treatment, and the body weight, abdominal circumference and 24 h urine volume of the two
groups were recorded before and after treatment.Results:Compared with before treatment, the serum TSH level, body weight and abdominal
circumference of the two groups decreased, and the FT3, FT4, T3 and T4 levels and 24 h urine volume increased (P<0.05); compared
with the control group, the serum TSH level, body weight and abdominal circumference of the experiment group were lower, and
the FT3, FT4, T3, T4 levels and 24 h urine volume were higher (P<0.05); the clinical total effective rate of the experiment group was
higher than that of the control group (P<0.05).Conclusion:Aztreonam combine with entecavir in the treatment of patients with hepatitis
B liver cirrhosis primary peritonitis has a better clinical efficacy, which could be related to the improvement of the thyroid hormone level
and the decrease of the inflammatory reaction. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
